Phesgo pdf
WebMay 2, 2024 · Phesgo (1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase per 15 mL) single-dose vial: 50242-0245-xx Phesgo (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase per 10 mL) single-dose vial: 50242-0260-xx VII. References (STANDARD) 1. Phesgo [package insert]. WebJan 1, 2024 · for PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Breast Cancer The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for PHESGO effective January 1, 2024. TYPE CODE DESCRIPTION Diagnosis: ICD-10-CM C50.011–C50.019 C50.111–C50.119 C50.211–C50.219 C50.311–C50.319 …
Phesgo pdf
Did you know?
WebPHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). WebPHESGO™ (pertuzumab, trastuzumab and hyaluronidase-zzxf) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2024, …
WebPHESGO ™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). WebJun 29, 2024 · Basel, 29 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo™, a fixed-dose combination of Perjeta® (pertuzumab) and...
WebPhesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Effective: 7/07/2024 Page 2 of 5 . Phesgo will be used in combination with chemotherapy for one of the following (A or B): A. Use as neoadjuvant treatment: o Patient has locally advanced; inflammatory, or early stage breast cancer (either greater than 2cm in diameter or node positive); WebWhat does PHESGO treat? PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: • use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, infl ammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter
WebPHESGO is a fixed-dose subcutaneous formulation with PERJETA®(pertuzumab) and trastuzumab that’s administered in ~5 minutes*1 *Refers to actual PHESGO injection time …
gatehouse php new hampshireWebPhesgo contains the active substances pertuzumab and trastuzumab. For more information about the use of Phesgo and the other medicines the patients will receive, see the … gatehouse pittsburgh mercyWebPHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti … davis city ia mapWebMar 1, 2024 · • PHESGO recognizes the cancer cells in the body called “human epidermal growth factor 2” or HER2 for short. HER2 is found in large amounts on the surface of … gatehouse philly yelpWebPHESGO has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous trastuzumab when administered alone. Do … gatehouse philadelphia navy yardWebNov 16, 2024 · Injection: PHESGO is a clear to opalescent, and colorless to slightly brownish solution provided as: 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15 mL (80 mg, 40 mg ... 4 CONTRAINDICATIONS. PHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, or trastuzumab, or hyaluronidase, … gatehouse philadelphia paWebJan 1, 2024 · Phesgo™ (pertuzumab, trastuzumab and hyaluronidase-zzxf) (Subcutaneous) Document Number: IC-0553 Last Review Date: 01/01/2024 Date of Origin: 08/04/2024 Dates Reviewed: 08/2024, 09/2024, 01/2024 I. Length of Authorization Coverage is provided for six months and may be renewed. gatehouse philly navy yard